SSY GROUP (02005) announced that the group has obtained a drug production registration approval from China's National Medical Products Administration for Sodium Glycerophosphate Injection (10ml: 2.16g). Classified as a chemical drug category 4, the product is considered to have passed the consistency evaluation, making SSY GROUP the third domestic company to receive this approval. Sodium Glycerophosphate Injection is a nutritional medication primarily used as a phosphorus supplement for adult parenteral nutrition and for patients with phosphorus deficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments